Therapeutic Peptides: Current Applications and Future Directions - A Detailed Summary
- May 10
- 10 min read
The National Library of Medicine’s National Center for Biotechnology Information features the article “Therapeutic peptides: current applications and future directions,” and this article provides a detailed summary of the key points, historical context, scientific developments, and future outlook presented in that publication. The article explains how therapeutic peptides have become an important and rapidly evolving class of pharmaceutical agents, supported by major advances in peptide discovery, synthesis, modification, delivery, and clinical development.
What Are Therapeutic Peptides?
Therapeutic peptides are pharmaceutical agents made from short chains of amino acids. The article describes them as a unique drug class, generally smaller than large biologics such as antibodies, but often more complex and target-specific than many traditional small-molecule drugs.
Peptides naturally occur throughout the body and often act as hormones, neurotransmitters, growth factors, receptor ligands, or signaling molecules. Because of this, many peptide drugs are designed to mimic or modify biological processes that already exist in nature.
The article emphasizes that peptide therapeutics are especially valuable because they can bind biological targets with high affinity and specificity. In many cases, they interact with receptors on the surface of cells and trigger specific cellular responses. This makes them useful across a wide range of therapeutic research areas, including metabolic disease, cardiovascular disease, gastrointestinal disease, oncology, infectious disease, pain management, and hormone-related conditions.
The Historical Development of Peptide Drugs
One of the article’s major points is that peptide drug development has a long history, beginning with the discovery and use of natural hormones.
The most important early example is insulin, which was first isolated in 1921 and became the first commercial peptide drug in 1923. The article describes insulin as one of the most significant achievements in drug discovery because it transformed the treatment of diabetes.
For much of the twentieth century, insulin production relied heavily on animal-derived sources, such as bovine and porcine insulin. Over time, advances in biotechnology made recombinant human insulin possible, improving production capacity and helping meet clinical demand.
The article also notes that the first half of the twentieth century saw the discovery of other life-saving bioactive peptides, including adrenocorticotrophic hormone. From the 1950s through the 1990s, researchers identified more peptide hormones and receptors with therapeutic potential. During this period, advances in protein purification, sequencing, synthesis, and structural analysis helped accelerate the development of peptide drugs.
By the end of the twentieth century, nearly 40 peptide drugs had been approved worldwide. These included synthetic and recombinant examples such as synthetic oxytocin, synthetic vasopressin, and recombinant human insulin.
A New Era of Peptide Drug Development
The article explains that peptide drug development entered a new era in the twenty-first century. Advances in structural biology, recombinant biologics, peptide chemistry, analytical technology, and drug design have significantly expanded what researchers can do with peptides.
Modern peptide drug development now includes a sophisticated process involving:
Peptide drug discovery
Peptide design
Peptide synthesis
Structural modification
Activity evaluation
Delivery strategy development
Optimization for stability and function
The article notes that since 2000, many non-insulin peptide drugs have been approved worldwide. Importantly, newer peptide drugs are not limited to simple hormone mimics. They now include biomimetic peptides, venom-derived peptides, GLP analogues, receptor agonists and antagonists, antimicrobial peptides, and peptide-based diagnostic agents.
Examples discussed in the article include enfuvirtide, a peptide used in HIV-1 combination therapy; ziconotide, a cone-snail-derived peptide used for severe chronic pain; teduglutide, a GLP-2 analogue used in short bowel syndrome; and liraglutide, a GLP-1 receptor agonist used in type 2 diabetes management.
This reflects one of the article’s central themes: peptide therapeutics have expanded far beyond their earliest hormone-based roots.
Current Applications of Therapeutic Peptides
The article highlights that peptide drugs are now used across many therapeutic categories. These include metabolic disorders, cancer, pain, cardiovascular disease, gastrointestinal conditions, respiratory disease, urology, endocrine disorders, and antimicrobial applications.
One of the most commercially successful peptide categories discussed is GLP-1 receptor agonists. The article notes that GLP-1 analogues became top-selling peptide drugs, especially in the context of type 2 diabetes treatment. Drugs such as dulaglutide, liraglutide, and semaglutide are identified as major examples of peptide-based pharmaceutical success.
The article also lists peptide drugs connected to many other targets and indications, including:
GLP-2 receptor peptides for short bowel syndrome
GC-C receptor peptides for irritable bowel syndrome with constipation and chronic idiopathic constipation
GnRH receptor peptides for prostate cancer
N-type calcium channel peptides for severe chronic pain
Somatostatin receptor peptides for Cushing’s disease and neuroendocrine tumors
Melanocortin receptor peptides for sexual desire disorder and chronic weight-management indications
PTH receptor peptides for osteoporosis
Angiotensin II-related peptide drugs for septic shock
Peptide-based agents for anemia, respiratory distress syndrome, and hyperparathyroidism
The article’s broader point is that peptide drugs are no longer a niche area of pharmaceutical development. They have become a significant and expanding part of the global drug market.
Why Peptides Are Attractive as Therapeutic Agents
The article compares peptides with both small-molecule drugs and large biologics, explaining that peptides occupy a valuable middle ground.
Small molecules often have advantages such as lower production costs, oral delivery potential, and the ability to enter cells. However, they may lack specificity and may struggle to disrupt large protein-protein interactions because of their small size.
Large biologics, such as antibodies and therapeutic proteins, can be highly specific and effective, but they are often more expensive to produce and may carry greater immunogenicity concerns.
Peptides offer several attractive features:
High target specificity
Strong binding affinity
Lower immunogenicity compared with many larger biologics
Ability to interact with large protein surfaces
Potential to modulate protein-protein interactions
Structural flexibility
Biological familiarity because many peptides are derived from natural signaling molecules
The article especially emphasizes the ability of peptides to interact with protein-protein interactions, which are involved in many cellular processes and disease pathways. Because peptides are larger and more flexible than many small molecules, they may be better suited for targeting these broad interaction surfaces.
The Main Challenges of Peptide Drugs
While the article is optimistic about therapeutic peptides, it also clearly explains their limitations.
The two major intrinsic drawbacks are:
1. Poor Membrane Permeability
Many peptides cannot easily cross cell membranes. This limits their ability to reach intracellular targets. The article notes that most peptides in active clinical development target extracellular receptors or other cell-surface targets.
This is one reason why many peptide drugs are designed to act on receptors outside the cell rather than inside the cell.
2. Poor In Vivo Stability
Natural peptides are vulnerable to enzymatic breakdown. Their amide bonds can be hydrolyzed or degraded in the body, often resulting in short half-lives and rapid elimination.
This means that many peptides require structural modification, formulation strategies, or delivery innovations to become practical therapeutic agents.
The article frames these drawbacks not only as challenges, but also as opportunities. Much of modern peptide drug development focuses on overcoming these limitations through chemical modification, sequence optimization, delivery technology, and improved synthesis methods.
Peptide Drug Discovery: From Natural Hormones to Rational Design
The article explains that early peptide drug discovery often began with natural hormones and peptides already found in the body. These included insulin, GLP-1, somatostatin, GnRH, vasopressin, and oxytocin.
Over time, researchers began modifying natural peptide sequences to improve stability, potency, selectivity, and pharmacological behavior.
For example, GLP-1 is a natural peptide involved in insulin regulation, but it has a very short half-life in the body. Extensive modification of GLP-1-like peptides led to important drugs such as dulaglutide, liraglutide, and semaglutide.
Similarly, modification of GnRH led to peptide drugs such as leuprolide and degarelix, which are used in hormone-related disease contexts.
The article also discusses peptides derived from natural products, including venom peptides from animals such as snakes, scorpions, and cone snails. These peptides often interact with ion channels or receptors and may have powerful biological activity. Ziconotide, derived from cone snail venom, is presented as an example of a natural-product peptide adapted for therapeutic use.
Non-Ribosomal Peptides and Natural Product Discovery
Another important category discussed in the article is non-ribosomal peptides, or NRPs. Unlike standard peptides produced through ribosomal protein synthesis, NRPs are made through specialized enzymatic pathways.
NRPs are scientifically exciting because their structures can be highly diverse and biologically powerful. However, the article also notes that their synthesis and structure-activity relationship studies can be challenging.
Rational Peptide Design and Protein-Protein Interactions
A major modern direction in the article is rational peptide design.
As proteomics and structural biology have advanced, researchers have identified many protein-protein interactions involved in disease. These interactions can be difficult for small molecules to target effectively because the binding surfaces are often large and complex.
Peptides can be designed to mimic key regions of proteins involved in these interactions. Researchers use structural data, computational modeling, and bioinformatics to identify important amino acid residues known as “hotspots.” These hotspots contribute significantly to binding energy and can guide the design of peptide modulators.
The article explains that rationally designed peptides may then be optimized through cyclization, backbone modification, substitution of non-essential residues, or stabilization of secondary structures such as helices, turns, hairpins, and extended conformations.
This represents a major shift in peptide discovery: from simply copying natural peptides to designing new peptides with desired biochemical and physiological properties.
Phage Display and Modern Screening Technologies
The article also describes phage display as an important technology in peptide drug discovery.
Phage display allows researchers to engineer peptides on the surface of bacteriophages and screen large libraries for ligands that bind specific biological targets. This makes it a powerful method for identifying new peptide candidates.
The article notes that phage display has been used to discover peptide ligands for membrane receptors, growth factor pathways, and other therapeutic targets.
It also discusses newer display technologies and approaches, including:
Chemically modified phage-display peptides
Mirror-image phage display
mRNA display
Ribosomal display
Macrocyclic peptide discovery
Peptides containing D-amino acids or unnatural amino acids
These technologies expand the diversity of peptides that can be discovered and optimized, helping researchers identify candidates with improved stability, binding, or biological activity.
Peptide Synthesis and Production
After discovery, peptide candidates must be produced reliably and efficiently. The article explains that both chemical and biological production methods are used.
A major technology discussed is solid-phase peptide synthesis, or SPPS. Developed by Merrifield in 1963, SPPS became one of the most important methods in modern peptide chemistry.
SPPS allows amino acids to be assembled step-by-step on a solid resin. The article explains that this process made peptide synthesis more efficient and eventually enabled automated peptide synthesizers.
SPPS has several advantages:
It supports controlled peptide assembly
It can produce relatively clean crude peptide material
Impurities are often easier to identify
It supports modifications and cyclization strategies
It plays a major role in modern peptide manufacturing
The article also mentions common SPPS strategies, including Fmoc-SPPS and Boc-SPPS, which use different protecting groups during peptide assembly.
Biological production methods, including recombinant DNA technology, are also important for certain peptide drugs, especially when larger-scale biological expression systems are needed.
Peptide Modification and Optimization
A recurring theme throughout the article is that natural peptides often need to be modified before they can become useful drugs.
Modification strategies are used to improve:
Stability
Half-life
Receptor selectivity
Potency
Solubility
Resistance to enzymatic degradation
Delivery properties
Pharmacological activity
The article discusses examples such as attaching fatty acids, modifying amino acid sequences, creating analogues, cyclizing peptides, altering backbones, and incorporating unnatural amino acids.
These strategies help overcome the two major peptide limitations: poor membrane permeability and poor in vivo stability.
Liraglutide is one example mentioned in the article. It is a GLP-1 analogue modified with a fatty acid chain, which helps extend its duration of action.
Peptides in the Pharmaceutical Market
The article emphasizes that peptide drugs have become commercially significant. It notes that peptide drugs accounted for more than $70 billion in worldwide sales in 2019, more than doubling from 2013.
The article also highlights that several top-selling peptide drugs are GLP-1 analogues. This illustrates how peptide drugs can move from specialized research areas into major global pharmaceutical markets.
In addition to approved drugs, the article states that more than 170 peptides were in active clinical development at the time of publication, with many more in preclinical studies.
This supports the authors’ view that therapeutic peptides will continue to attract investment, research, and commercial interest.
The Future of Therapeutic Peptides
The article’s conclusion is optimistic. It argues that therapeutic peptides have become a unique and promising class of agents because of their biochemical characteristics and therapeutic potential.
The authors explain that the field has evolved from natural hormone discovery toward advanced rational design and technological innovation. Modern peptide development now benefits from breakthroughs in:
Molecular biology
Peptide chemistry
Structural biology
Drug delivery technology
Recombinant production
Computational design
High-throughput screening
Chemical and genetic modification methods
The article predicts continued long-term success for therapeutic peptides because they have broad potential across many disease categories and because the field continues to overcome traditional limitations.
The authors also emphasize that future success depends on improving peptide delivery, stability, activity, and manufacturability. As these technologies improve, peptides may become even more versatile as drug candidates.
Key Takeaways from the Article
The article makes several important points:
First, therapeutic peptides have a long history, beginning with natural hormones such as insulin, oxytocin, vasopressin, and GnRH.
Second, peptide drug development has advanced dramatically because of improvements in synthesis, purification, sequencing, recombinant production, structural biology, and analytical technologies.
Third, peptides offer a valuable balance between small molecules and biologics. They can provide high specificity, strong binding, and the ability to interact with large protein surfaces.
Fourth, peptides face important challenges, especially poor membrane permeability and limited stability in the body.
Fifth, modern peptide design focuses heavily on solving these challenges through sequence modification, cyclization, backbone changes, fatty acid conjugation, unnatural amino acids, and advanced delivery strategies.
Sixth, peptide drugs are already used in many therapeutic areas, including diabetes, cancer, gastrointestinal disease, cardiovascular disease, pain, hormone-related conditions, and infectious disease.
Seventh, the field is moving beyond simple hormone mimics into rationally designed peptides, venom-derived peptides, non-ribosomal peptides, macrocyclic peptides, and peptide candidates discovered through display technologies.
Finally, the article presents therapeutic peptides as a rapidly growing and commercially important field with strong future potential.
Final Summary
“Therapeutic peptides: current applications and future directions” presents therapeutic peptides as one of the most important areas of modern pharmaceutical research. The article explains how peptides have evolved from naturally discovered hormones into sophisticated, engineered drug candidates supported by advanced chemistry, biotechnology, computational design, and delivery science.
While peptides still face limitations in stability and cell permeability, the article shows that these challenges are being actively addressed through modern drug design strategies. With more than 80 peptide drugs already approved globally and many more in clinical or preclinical development, therapeutic peptides are positioned to remain a major focus of pharmaceutical research, clinical innovation, and biotechnology investment.
Credit
This blog article is a summary and educational discussion of the article “Therapeutic peptides: current applications and future directions,” featured by the National Library of Medicine’s National Center for Biotechnology Information. Credit is given to the original authors and publication for the research, analysis, tables, and scientific discussion summarized here.
Editor’s Note: This article is intended solely for research, educational, and industry discussion purposes. It does not promote, recommend, or imply any personal use, medical use, health benefit, treatment outcome, or therapeutic application of peptides or related compounds.
Comments